Chemotherapy overall objective response rate

The primary endpoint was the overall objective response rate. Of the 444 patients enrolled in the study, 78 patients (17.6%) went off-study prior to receiving one cycle of chemotherapy. The main reason for withdrawal was insufficient tumor tissue for ERCCI mRNA assessment (42 patients [9.4%]). Of the 366 patients who completed the study, 346 were evaluable for response and 366 for progression-free and overall survival and safety. Objective response was observed in 53 patients (39.3% 95% confidence interval [Cl], 31.4%-47.8%) in the control arm and 107patients (50.7% 95%CI, 44%-57.5% / =. 019) in the genotypic arm (90). 

Intravenous Chemotherapy. The most effective chemotherapeutic agent for bladder carcinoma is cisplatin with objective responses ranging from 26% to 56%, with complete responses seen in 0%-14%. In a study of 121 patients, MVAC (methotrexate, vinblastine, doxorubicin [Adriamycin] and cisplatin) demonstrated an overall response rate of 72% one half of the responses being complete (Sternberg et al. 1989). The median survival was 13 months. CISCA (cisplatin, doxorubicin, and cyclophosphamide) was compared to MVAC MVAC proved to be superior with a difference in median survival of 82 versus 40 weeks (Logothetis... 

---